文献速递肿瘤 PET/CT核素与放射性配体治疗

转移性去势抵抗性前列腺癌患者PSMA PET/CT疗效评估新框架(RECIP 1.0):一项国际多中心研究

Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study.
PubMed 文献 · J Nucl Med · 2022-04-14

本研究为国际多中心回顾性研究,纳入124例接受177Lu-PSMA治疗并在基线和12周时行PSMA PET/CT的转移性去势抵抗性前列腺癌(mCRPC)男性,开发了RECIP 1.0疗效评估框架及PSA+RECIP复合反应分类。RECIP-PD患者总生存期短于RECIP-SD和RECIP-PR患者,PSA+RECIP在识别应答者和进展者方面的C指数优于单独PSA。

要点

  • RECIP 1.0结合新发病灶出现与PSMA-VOL变化,将疗效分为完全缓解、部分缓解、疾病进展和疾病稳定。
  • RECIP-PD患者中位OS为8.3个月,短于RECIP-SD的13.1个月和RECIP-PR的21.7个月(均P<0.001)。
  • PSA+RECIP识别应答者和进展者的C指数分别为0.65和0.66,优于单独PSA的0.62和0.63。

核心结论

  • RECIP 1.0评估的PSMA PET/CT对总生存期具有预后价值,可作为反应生物标志物监测mCRPC男性177Lu-PSMA的早期疗效。
  • PSA+RECIP可作为mCRPC临床试验设计中的新型复合终点。

研究设计与样本

  • 国际多中心回顾性研究,纳入124例接受177Lu-PSMA治疗且在基线和12周时行PSMA PET/CT的mCRPC男性。
  • 基线和中期PET/CT扫描由3名设盲读者共识判读新发病灶,病灶分割获得总PSMA阳性肿瘤体积(PSMA-VOL)。

主要发现

  • RECIP-PD患者(n=39)中位OS为8.3个月,短于RECIP-SD患者(n=47;13.1个月;P<0.001)和RECIP-PR患者(n=38;21.7个月;P<0.001)。
  • PSA+RECIP识别应答者的C指数为0.65,优于单独PSA的0.62(P=0.028)。
  • PSA+RECIP识别进展者的C指数为0.66,优于单独PSA的0.63(P=0.044)。

关键数值与推荐

  • RECIP-CR:中期PET/CT无任何PSMA配体摄取。
  • RECIP-PR:PSMA-VOL下降≥30%且无新发病灶出现。
  • RECIP-PD:PSMA-VOL增加≥20%且出现新发病灶。
  • RECIP-SD:不符合RECIP-PR或RECIP-PD的任何情况。
  • PSA+RECIP定义应答为PSA下降≥50%或RECIP-PR/CR,进展为PSA升高≥25%或RECIP-PD。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our objective was to develop version 1.0 of a novel framework for response evaluation criteria in prostate-specific membrane antigen (PSMA) PET/CT (RECIP) and a composite response classification that combines responses by prostate-specific antigen (PSA) measurements and by RECIP 1.0 (PSA + RECIP). Methods: This was an international multicenter, retrospective study. One hundred twenty-four men with metastatic castration-specific prostate cancer (mCRPC) who underwent 177Lu-PSMA therapy and received PSMA PET/CT at baseline and at an interim time point of 12 wk were included. Pairs of baseline interim PET/CT scans were interpreted by consensus among 3 masked readers for appearance of new lesions. Tumor lesions were segmented, and total PSMA-positive tumor volume (PSMA-VOL) was obtained. Appearance of new lesions and changes in PSMA-VOL were combined to develop RECIP 1.0, which included classifications of complete response (RECIP-CR: absence of any PSMA-ligand uptake on interim PET/CT), partial response (RECIP-PR: decline ≥ 30% in PSMA-VOL and no appearance of new lesions), progressive disease (RECIP-PD: increase ≥ 20% in PSMA-VOL and appearance of new lesions), and stable disease (RECIP-SD: any condition but RECIP-PR or RECIP-PD). Changes in PSA levels at 12 wk by Prostate Cancer Working Group Criteria 3 were recorded. PSA + RECIP results were defined as response (PSA decline ≥ 50% or RECIP-PR/CR) or progression (PSA increase ≥ 25% or RECIP-PD). The study's primary outcome measure was the prognostic value of RECIP 1.0 for overall survival (OS). The secondary outcome measure was the prognostic accuracy (C-index) of PSA + RECIP versus PSA responses. Results: Patients with RECIP-PD (n = 39; 8.3 mo) had a shorter OS than patients with stable disease (RECIP-SD) (n = 47; 13.1 mo; P < 0.001) or RECIP-PR (n = 38; 21.7 mo; P < 0.001). In identifying responders and progressors, PSA + RECIP had C-indices superior to those of PSA only: 0.65 versus 0.62 (P = 0.028) and 0.66 versus 0.63 (P = 0.044), respectively. Conclusion: PSMA PET/CT by RECIP 1.0 is prognostic for OS and can be used as a response biomarker to monitor early efficacy of 177Lu-PSMA in men with mCRPC. PSA + RECIP may be used as a novel composite endpoint in mCRPC clinical trial design.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Gafita A, Rauscher I, Weber M, et al. Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study. J Nucl Med. 2022. PMID: 35422442. doi:10.2967/jnumed.121.263072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。